Identification of Two Novel Variants of the DMD Gene in Chinese Families with Duchenne Muscular Dystrophy

References

• Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(9):872–876. doi:10.1038/sj.embor.7400221
   PubMed Web of Science ®Google Scholar
• Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141. doi:10.1186/s13023-020-01430-8
   PubMed Web of Science ®Google Scholar
• Schade Van Westru SM, Hoogerwaard EM, Dekker L, et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology. 2011;77(1):62–66. doi:10.1212/WNL.0b013e318221ad14
   PubMed Web of Science ®Google Scholar
• Mercier S, Toutain A, Toussaint A, et al. Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age. Eur J Hum Genet. 2013;21(8):855–863. doi:10.1038/ejhg.2012.269
   PubMed Web of Science ®Google Scholar
• Anaya-Segura MA, Garcia-Martinez FA, Montes-Almanza LA, et al. Non-invasive biomarkers for Duchenne muscular dystrophy and carrier detection. Molecules. 2015;20(6):11154–11172. doi:10.3390/molecules200611154
   PubMed Web of Science ®Google Scholar
• Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. doi:10.1038/s41572-021-00248-3
   PubMed Web of Science ®Google Scholar
• Wang L, Xu M, Li H, et al. Genotypes and Phenotypes of DMD Small Mutations in Chinese Patients with Dystrophinopathies. Front Genet. 2019;10:114. doi:10.3389/fgene.2019.00114
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016;53(3):145–151. doi:10.1136/jmedgenet-2015-103387
   PubMed Web of Science ®Google Scholar
• Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–267. doi:10.1016/S1474-4422(18)30024-3
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu Y, Liu D, et al. A modified multiplex ligation-dependent probe amplification method for the detection of 22q11.2 copy number variations in patients with congenital heart disease. BMC Genomics. 2015;16:364. doi:10.1186/s12864-015-1590-5
   PubMed Web of Science ®Google Scholar
• Liang Q, Qin H, Ding Q, et al. Molecular and clinical profile of VWD in a large cohort of Chinese population: application of next generation sequencing and CNVplex ® technique. Thromb Haemostasis. 2017;117(8):1534. doi:10.1160/TH16-10-0794
   PubMed Web of Science ®Google Scholar
• Li Q, Wang K. InterVar: clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. Am J Hum Genet. 2017;100(2):267–280. doi:10.1016/j.ajhg.2017.01.004
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30
   PubMed Web of Science ®Google Scholar
• Chen C, Chen H, Zhang Y, et al. TBtools: an integrative toolkit developed for interactive analyses of big biological data. Mol Plant. 2020;13(8):1194–1202. doi:10.1016/j.molp.2020.06.009
   PubMed Web of Science ®Google Scholar
• Lindeboom RG, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet. 2016;48(10):1112–1118. doi:10.1038/ng.3664
   PubMed Web of Science ®Google Scholar
• Okubo M, Minami N, Goto K, et al. Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations. J Hum Genet. 2016;61(6):483–489. doi:10.1038/jhg.2016.7
   PubMed Web of Science ®Google Scholar
• Saad FA, Mostacciuolo ML, Trevisan CP, et al. Novel mutations and polymorphisms in the human dystrophin gene detected by double-strand conformation analysis. Hum Mutat. 1997;9(2):188–190. doi:10.1002/(SICI)1098-1004(1997)9:2<188::AID-HUMU15>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Schreiber A, Brochard S, Rippert P, et al. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. Dev Med Child Neurol. 2018;60(2):185–191. doi:10.1111/dmcn.13590
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bonnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394(10213):2025–2038. doi:10.1016/S0140-6736(19)32910-1
   PubMed Web of Science ®Google Scholar
• Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–487. doi:10.1002/mus.24332
   PubMed Web of Science ®Google Scholar
• Haas M, Vlcek V, Balabanov P, et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscular Disord. 2015;25(1):5–13. doi:10.1016/j.nmd.2014.11.011
   PubMed Web of Science ®Google Scholar
• Niks EH, Aartsma-Rus A. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Th. 2017;17(2):225–236. doi:10.1080/14712598.2017.1271872
   PubMed Web of Science ®Google Scholar
• O’Brien A, Cohn RD. Genome Editing for Muscle Gene Therapy. In: Duan D, Mendell JR, editors. Muscle Gene Therapy. Cham: Springer International Publishing; 2019:275–287.
   Google Scholar
• Takeda S, Clemens PR, Hoffman EP. Exon-Skipping in Duchenne Muscular Dystrophy. J Neuromuscular Dis. 2021;8(s2):S343–S358. doi:10.3233/JND-210682
   PubMedGoogle Scholar
• Wagner KR, Kuntz NL, Koenig E, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64(3):285–292. doi:10.1002/mus.27347
   PubMed Web of Science ®Google Scholar
• Alfano LN, Charleston JS, Connolly AM, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine. 2019;98(26):e15858. doi:10.1097/MD.0000000000015858
   PubMed Web of Science ®Google Scholar
• Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270–e2282. doi:10.1212/WNL.0000000000009233
   PubMed Web of Science ®Google Scholar
• Roshmi RR, Yokota T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drug Today. 2019;55(10):627–639. doi:10.1358/dot.2019.55.10.3045038
   PubMed Web of Science ®Google Scholar
• Gushchina LV, Frair EC, Rohan N, et al. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021;32(17–18):882–894. doi:10.1089/hum.2020.286
   PubMed Web of Science ®Google Scholar
• Dara M, Razban V, Talebzadeh M, Moradi S, Dianatpour M. Using CRISPR/Cas9 System to Knock out Exon 48 in DMD Gene. Avicenna J Med Biotechnol. 2021;13(2):54–57. doi:10.18502/ajmb.v13i2.5517
   PubMedGoogle Scholar